Introduction
Angiotensin II (Ang II) acts on two distinct receptor subtypes, type 1 (AT1) and type 2 (AT2) receptors (1 -4) . The AT2 receptor is developmentally regulated and exerts antiproliferative and proapoptotic actions in several cell types lature causes vasodilation and counteracts the AT1-mediated pressor effect (12) , suggesting that dysregulated expression of Ang II receptor subtypes may be involved in the altered regulation of blood pressure and cardiovascular homeostasis. However, it remains to be determined whether the AT2 receptor plays a role in the pathogenesis of hypertension and related disorders.
We previously reported that the AT2 receptor is expressed in cultured mesangial cells (MC) obtained from normotensive Wistar-Kyoto rats (WKY) but not in MC from strokeprone spontaneously hypertensive rats (SHRSP), whose proliferation activity is much higher than that of MC from WKY (13) . The reason for this difference has not been determined, but we found that the AT2 receptor expression in mouse fibroblast R3T3 cells is markedly upregulated by a transcriptional factor interferon regulatory factor (IRF)-1 (14) . We therefore hypothesize that the expression of the AT2 receptor in MC is also regulated by IRF-1. We further suggest that the AT2 receptor may control mesangial proliferation and hence play a modulatory role in glomerular function. The findings also raise the possibility that AT1 receptormediated effects are exaggerated in the kidney of SHRSP, thereby contributing to the development of hypertension and related renal injury. Indeed, it has been shown that the reninangiotensin system (RAS) is inappropriately activated in SHRSP in the plasma and kidney (15) , and that the treatment to block Ang II generation or AT1 receptor signaling leads to significant amelioration of renal injury in these rats (16, 17) . Moreover, it has been reported that the early administration of angiotensin-converting enzyme (ACE) inhibitors in young SHRSP, and also in SHR, prevents subsequent development of hypertension, even after the administration is stopped (18, 19) . These studies strongly suggest that the enhanced AT1-mediated effects during early normotensive periods in these rats play a critical role in later tissue remodeling, leading to hypertension and related disorders.
In the present study, we examined developmental changes in the expression of AT1 and AT2 receptors in the kidney of SHRSP, comparing them with those in WKY. We also investigated the regulation and functional role of the AT2 receptor in cultured MC obtained from WKY and SHRSP.
Methods

Animals, Tissues and Cells
WKY and SHRSP at embryonic day 20, postnatal day 1, and 1, 4 and 20 weeks of age were obtained from Shionogi Research Laboratories, Osaka, Japan. All procedures were in accordance with our institutional guidelines for animal research. Kidneys harvested after decapitation were frozen in liquid nitrogen and stored at 80˚C until assay. Cultured MC were prepared from the kidneys of 20-week-old WKY and SHRSP using the explant method (13) . Cells were maintained in RPMI-1640 medium containing 10% fetal calf serum (FCS) and used between passages 5 and 10. For induction of the AT2 receptor, experiments were performed in a 7-day postconfluent state, as previously reported (13) .
Membrane Preparation and Receptor Binding Assay
Membrane preparation and receptor binding assays were performed as described previously (3, 20) . Frozen kidneys were broken into pieces and homogenized with a polytron homogenizer in 5 volumes of homogenizing buffer (20 mM phosphate buffer, pH 7.4, containing 100 µg/ml phenylmethylsulfonyl fluoride and 10 µg/ml each of aprotinin, leupeptin, and pepstatin A). The homogenate was centrifuged at 600 g for 5 min and the supernatant was centrifuged at 25,000 g for 30 min. The final pellet was resuspended in homogenizing buffer and aliquots were stored at 80˚C within 48 h until binding assay. Protein content was determined using a commercial kit (Bio-Rad Labs., Hercules, USA) with bovine serum albumin (BSA) as a standard.
Competitive binding assays were performed with 30 µg protein of crude membrane preparation in a total volume of 100 µl of 20 mM Tris, pH 7.4, with 0.25% BSA (3, 20) .
Ci/mmol; New England Nuclear, Boston, USA) was added at a final concentration of 200 pM. Unlabeled AT2-selective CGP42112 (Novartis, Basel, Switzerland), AT1-selective CV-11974 (Takeda Chemical Industries, Osaka, Japan), and Ang II (Peptide Institute, Osaka, Japan) were added at final concentrations ranging from 10 10 M to 10 5 M. Ang II at 1 µM was used to determine nonspecific binding. For Scatchard analysis, saturation studies were performed with increasing concentrations of 125 I-CGP42112 (1,400 Ci/mmol), prepared by iodination with the chloramine-T method, and 30 µg crude membrane per tube (20) . Incubations proceeded for 90 min at 22˚C, and bound and free ligands were separated through GF/C filters (Whatman, Maidstone, UK) by washing with 15 ml ice-cold 25 mM Tris, pH 7.4. The receptor density (maximum binding capacity, Bmax) and the dissociation constant (Kd) were calculated from the Scatchard plot followed by linear regression analysis with duplicate samples for each point as described previously (20) .
Northern Blot Analysis
Total RNA was extracted from tissues and cells with TRIzol reagent (Gibco BRL, Gaithersburg, USA) and subjected to Northern blot analyses (13, 20) . Total RNA (100 µg/lane) was electrophoresed on 1% agarose gel containing 2% formaldehyde and transferred onto a nylon membrane (Biodyne; Pall BioSupport, Glen Cove, USA). Hybridization proceeded at 42˚C overnight in 50% formamide, 4 SSC, 5 Denhardt's solution, 0.5% SDS, and 75 µg/ml denatured salmon sperm DNA with 32 P-labeled probes for a HindIII/SacI fragment of rat AT2 receptor cDNA (nucleotide 123/ 2,307) (3), or PCR-amplified rat AT1A receptor cDNA ( 132/ 719) which detects messages for both AT1A and AT1B receptors (1) . The membranes were washed twice at 55˚C in 0.5 SSC and 0.1% SDS for 20 min, and autoradiography was performed at 80˚C. As an internal control, the filter was rehybridized with a human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe (Clontech, Palo Alto, USA).
RT-PCR Analysis
RT-PCR was performed as described previously (13) . PCR primers used for the AT2 receptor were as follows: 5 -TTGCTGCCACCAGCAGAAAC-3 and 5 -GTGTGGGCC TCCAAACCATTGCTA-3 (13) . For identifying IRF-1, PCR primers were 5 -CCTGATGACCACAGCAGTTAC-3 and 5 -CTTCATCTCCGTGAAGACATG-3 (14) . PCR reaction was carried out with 30 cycles of 30 s of denaturation at 94˚C, 45 s of annealing at 58˚C and 1 min of extension at 72˚C. The PCR amplification for the AT2 receptor cDNA occurred linearly around this cycle range (13) . The expression of GAPDH by RT-PCR was used as a control.
Sequencing of the Promoter Region of the AT2 Receptor Gene
Rat genomic DNA was extracted from isolated glomeruli of WKY and SHRSP. The putative promoter region of the rat AT2 receptor gene including the IRF-binding element (14) was amplified from nucleotide 550 to 234 by PCR with following primers: sense, 5 -GGGCACTACATGGAACTT TAT-3 ; antisense, 5 -CTCCGTGGCTTTCTTTAAGAG-3 (21). The PCR product was sequenced by the cycle sequence method with a DNA sequencing kit (Applied Biosystems, Foster City, USA) in a thermal cycler (PCR2400, Perkin-Elmer, Foster City, USA). The sample was then subjected to an automated DNA sequencer (Model 373B, Applied Biosystems), followed by computer analysis.
IRF-1 Antisense Transfection and Interferon Treatment in Cultured MC
Transfection of antisense oligodeoxynucleotide (ODN) against IRF-1 mRNA to postconfluent WKY-MC was performed using the cationic lipofection method (22) with slight modifications. Sequences of IRF-1 antisense and sense ODN were as follows: antisense, 5 -GAATGATGCCCGAGATGC-3 ; sense, 5 -GCATCTCGGGCATCATTC-3 ( 106/ 89) (23) . Transfection of ODN into 7-day postconfluent cells expressing the AT2 receptor was performed with Transfectam Reagent (Promega, Madison, USA) according to the manufacturer's instructions. Cells were exposed to 5 µM ODN and the reagent in serum-free medium for 6 h. After change to growth medium containing 10% FCS, cells were incubated for 72 h and the receptor binding assay was performed as above. In a preliminary experiment, the transfection efficiency of fluorescent ODN into MC with this system was not high and estimated as being 30%. For induction of the AT2 receptor, MC upon reaching confluence were incubated with 100 U/ml of interferon (IFN)-α (human recombinant; R&D Systems, Minneapolis, USA) or IFN-γ (rat recombinant, R&D Systems) for 0.5 h to 24 h. After incubation, the AT2 receptor was assayed by RT-PCR and binding assay.
Proliferation Studies in Cultured MC
In order to investigate the role of the AT2 receptor in growth of MC from WKY and SHRSP, proliferation assays were performed with 3 H-thymidine (Amersham, Arlington Heights, USA) as previously described (13, 22, 24) . In brief, cells were cultured in 24-well plates with RPMI-1640/10% FCS until a 7-day postconfluent state (13) , and made quiescent under serum-free conditions with 10 µg/ml insulin, 10 µg/ml transferrin, 10 ng/ml selenium, and 0.1% BSA for 48 h (24) . After addition of 10 ng/ml platelet-derived growth factor (PDGF)-BB (Becton Dickinson Labware, Bedford, USA), cells were stimulated with 100 nM Ang II or CGP42112 (AT2-selective agonist) for 16 h in the presence or absence of 10 µM CV-11974 (AT1-selective antagonist) or PD123319 (AT2-selective antagonist; Park-Davis, Ann Arbor, USA). Cells were then labeled with 3 H-thymidine (final concentration, 10 µCi/ml) for 8 h, and the tracer incorporated into the cells was measured in a liquid scintillation counter.
Statistical Analysis
Results are expressed as the means SE. The analysis of variance followed by Scheffe's test was used for statistical analysis. Values of p 0.05 were considered to indicate statistical significance.
Results
Binding Studies for Ang II Receptor Subtypes in the Developing Rat Kidney
We first analyzed Ang II receptor subtypes of membrane preparations from the whole kidney of WKY and SHRSP at embryonic and neonatal stages (Fig. 1) . In the kidney of WKY at embryonic day 20, AT2-selective CGP42112 at 10 ]Ang II binding to the membrane preparation, whereas AT1-selective CV-11974 at 10 6 M displaced only 20% of total Ang II binding (Fig. 1A,  left) . Thus, the kidney of fetal WKY expresses AT1 and AT2 receptors at a ratio of 1 4 at this stage. On the other hand, in the kidney of fetal SHRSP, CGP42112 displaced 60 -70% of total Ang II binding, while CV-11974 competed for 33% of this binding (Fig. 1A, right) . Thus, AT1 and AT2 receptors are expressed at a ratio of 1 2 in the fetal SHRSP kidney. These results suggest relatively lower ex-pression of the AT2 receptor and/or higher expression of the AT1 receptor in the kidney of SHRSP during this period.
To analyze the AT2 receptor expression more quantitatively, we next performed the selective binding assay using an AT2-selective ligand CGP42112 as a tracer. Representative Scatchard analysis of the AT2 receptor (Fig. 1B) revealed a higher receptor density (Bmax) in the WKY kidney with no significant difference in the Kd values ( 0.7 nM) between WKY and SHRSP. The Bmax values were decreased to a third of those in the fetal kidney at day 1, and to a sixth of those in the fetal kidney at day 7 in each strain (Fig. 1B, C) . The expression of the AT2 receptor in the kidney of SHRSP was significantly lower (by 30%) than that of age-matched WKY at embryonic day 20 and postnatal day 1 (Fig. 1C) . In the preparations from whole kidneys at 4 and 20 weeks of age, the AT2 receptor binding was below the detectable limit in both strains (not shown).
Northern Blot Analyses for AT1 and AT2 Receptors in the Developing Rat Kidney
We next examined the expression of AT1 and AT2 receptor messages in the developing rat kidney (Fig. 2) . Abundant expression of 3.5-kb AT2 receptor mRNA was detected at embryonic day 20 in the kidneys of both strains (Fig. 2A) . The AT2 receptor mRNA expression was rapidly decreased after birth through day 7 in each strain. The mRNA level in the kidneys was below the detectable limit at 4 and 20 weeks of age in both strains (not shown). The AT2 receptor mRNA level in the kidneys of fetal and neonatal SHRSP was significantly lower (by 40%) than that of age-matched WKY (Fig. 2B) , consistent with the results of the binding studies. The expression of AT1 receptor mRNA tended to be increased during this period, and there was no significant difference between the two strains (Fig. 2B) . Thus, the main finding is that AT2 receptor expression was attenuated in the SHRSP kidney during the perinatal period. These results correlate well with our previous in vitro observations, in which a significantly lower expression of the AT2 receptor was shown in cultured MC derived from SHRSP (13) .
Sequencing of the Promoter Region of the AT2 Receptor Gene
Our in vitro and in vivo data suggest that the expression of the AT2 receptor is impaired in the SHRSP kidney under certain conditions. In order to clarify whether there is a possible difference in cis-acting sequences, we compared part of the promoter region ( 495/ 255) of the AT2 receptor gene between WKY and SHRSP. We found no difference between the two strains in this region, which showed complete identity to the reported sequence of the Fisher rat (21), including IRF-binding motifs ( 475/ 451).
IRF-1 Dependence of AT2 Receptor Gene Expression in Cultured MC
We have already shown that the growth-dependent induction of AT2 receptor expression in mouse fibroblast R3T3 cells is regulated by an interplay of the transcriptional factors IRF-1 and IRF-2, with IRF-1 strongly upregulating the AT2 receptor expression (14) . We therefore examined whether IRF-1 is involved in the expression of the AT2 receptor in MC (Fig.  3) . IRF-1 gene expression paralleled well with the AT2 receptor gene expression in postconfluent WKY-MC, whereas no significant expression of IRF-1 or AT2 receptor was detected in SHRSP-MC (Fig. 3A) . 
I-CGP42112 binding in the membranes prepared from the whole kidney of WKY (left) and SHRSP (right) at embryonic day 20 ( ), postnatal day 1 ( ) and day 7 ( ). Representative data out of four independent experiments are shown. (C) Changes of the AT2 receptor density (Bmax) in the whole kidney of WKY (open columns) and SHRSP (closed columns) at embryonic day 20 (E20) and postnatal days 1 (1d) and 7 (7d). Mean SE. p 0.05, n 4.
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To examine whether blockade of IRF-1 affects the AT2 receptor expression, we treated WKY-MC expressing the AT2 receptor with IRF-1 antisense or sense ODN. Antisense ODN transfection showed a significant decrease of the AT2 receptor binding in MC, but IRF-1 sense ODN transfection did not (Fig. 3B) .
IRF-1 is induced by several cytokines, including IFN-γ and IFN-α (25, 26) . Treatment of cultured WKY-MC with IFN-γ resulted in an induction of AT2 receptor expression, which occurred as early as 30 min after exposure (Fig. 3C) . Interestingly, such induction was observed similarly in SHRSP-MC, and also with IFN-α (Fig. 3C) . Receptor binding assays confirmed the upregulation of AT2 receptor by IFNs in SHRSP-MC as well as in WKY-MC (Fig. 3D) .
Antiproliferative role of AT2 Receptor in Cultured MC
The AT2 receptor has been shown to mediate antiproliferative actions in several cell types (2, 5, 27 -31) , but its role in mesangial proliferation has not been characterized. We therefore examined the effects of AT2 receptor stimulation in growth of MC from WKY and SHRSP (Fig. 4) . Administration of 100 nM Ang II enhanced DNA synthesis in WKY-MC 2.5-fold; AT1-antagonist CV-11974 at 10 µM completely abolished this increase, whereas AT2-antagonist PD123319 at 10 µM significantly augmented Ang II-induced DNA synthesis (p 0.05) (Fig. 4A, left) . Thus, MC proliferation is stimulated by the AT1 receptor but inhibited by the AT2 receptor. To more directly confirm that MC growth inhibition is mediated by the AT2 receptor, we examined the effect of the AT2-agonist CGP42112. CGP42112 at 100 nM significantly inhibited PDGF-stimulated DNA synthesis, which effect was completely reversed by the addition of PD123319 (Fig. 4B, left) . In SHRSP-MC, on the other hand, basal DNA synthesis was more enhanced (2 -3-fold enhancement) than in WKY-MC, and DNA synthesis was increased by AT1 receptor stimulation but unaffected by AT2 receptor inhibition or stimulation with either PD123319 or CGP42112 (Fig. 4A, B, right) . Thus, the AT2 receptor stimulation exerts an antiproliferative effect in WKY-MC, but not in SHRSP-MC.
Discussion
Recent epidemiological evidence and animal experiments have indicated that the environmental factors during fetal and perinatal periods can program an individual for increased risk of hypertension or other cardiovascular disease in adulthood (32) . Among possible mechanisms for this perinatal programming, the RAS has been postulated to play an important role by affecting both vascular growth and renal development (27, 32) . Indeed, multiple gene knockout approaches have demonstrated an essential role for the RAS components in normal renal development as well as blood pressure homeostasis (1, 2, 9 -11, 27, 33, 34) . Furthermore, treatment of normal rats with an ACE inhibitor during the
Fig. 2. Northern blot analyses for AT2 receptor (AT2R) and AT1 receptor (AT1R) mRNA in the developing rat kidney. (A) Representative Northern blots for AT2 and AT1 receptor mRNA in the whole kidney of WKY and SHRSP at embryonic day 20 (E20) and postnatal days 1 (1d) and 7 (7d). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (B) Relative AT2 (upper) and AT1 receptor (lower) mRNA levels in the whole kidney of WKY (open columns) and SHRSP (closed columns) at embryonic day 20 (E20) and postnatal days 1 (1d) and 7 (7d). The relative mRNA level in each sample was determined as a ratio to the GAPDH mRNA level measured by densitometry. Mean SE. p 0.05, n 4.
A B first 2 weeks after birth causes irreversible renal abnormalities (35) . On the other hand, temporary treatment of young SHRSP and SHR with an ACE inhibitor or an AT1-receptor antagonist prevents the development of hypertension and renal injury after maturation (18, 19) . These studies strongly suggest that the appropriate Ang II signaling, via well-balanced AT1 and AT2 receptors, in the kidney during early life is critical for normal renal development, which should be a prerequisite for normal renal function and blood pressure regulation in later life.
In the present study, we reveal that the AT2 receptor is abundantly expressed in the fetal rat kidney and that its expression in the SHRSP kidney is significantly lower than that in the WKY kidney during the perinatal period (Figs. 1, 2) . The AT2 receptor is abundantly expressed in the fetal kidney, particularly in mesenchymal tissues, and decreases immediately after birth (7 -9) , though it continues to be expressed in certain tissues of the adult kidney in rats and humans. These include the glomeruli, presumably in the epithelium and mesangial area, as well as the proximal tubules and larger vessels (36, 37) , where the AT2 receptor may function to facilitate vasodilation, antiproliferation, apoptosis, bradykinin and nitric oxide stimulation, and regulation of tubular reabsorption (36 -38) . Since we have not investigated the localization of the AT2 receptor expression in the present study, the pathogenic significance of decreased expression of the receptor in the SHRSP kidney is unclear. However, recent reports using pharmacological analyses have shown that the AT2 receptor is present in the afferent arterioles in rabbits (39, 40) and rats (41) , and exerts endothelium-dependent vasodilation through a cytochrome P450 epoxygenase pathway (39 -41) . Of note, such AT2 receptor-mediated vasodilation of the afferent arterioles is greatly impaired in 4-week-old SHR (41) , suggesting a decreased AT2 receptor expression. Since an exaggerated vasoconstrictor action of Ang II on preglomerular vessels in young SHR is thought to be a key mechanism for the development of hypertension (41, 42) , the impaired AT2 receptor function may play a crucial role in the 
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pathogenesis of hypertension in SHR. Although the precise localization and functional role of the AT2 receptor expressed in the young rat kidney need to be further investigated, these observations suggest that the AT2 receptor may be required for accomplishing normal tissue remodeling and for modulating glomerular microcirculation during the early period of life. Multiple pieces of evidence have shown that the AT2 receptor exerts an antiproliferative effect in a variety of cells, including vascular smooth muscle cells, endothelial cells, fibroblasts, cardiocytes and renal interstitial cells (2, 5, 27 -31) . It also induces apoptosis in certain cell types (2, 6) . In the present study, we reveal that AT2 receptor stimulation also causes growth inhibition of MC derived from WKY (Fig. 4) . This effect is not exerted in SHRSP-MC, which virtually lack the expression of the AT2 receptor (Fig. 4) . Since SHRSP-MC exhibit a more pronounced proliferation activity than WKY-MC expressing the AT2 receptor (13), these results raise the possibility that the AT2 receptor, when activated by Ang II, may transmit antiproliferation signals to the cells in an autocrine/paracrine manner. It is also conceivable that the increased mesangial expression of the AT2 receptor, if any, may modulate mesangial proliferation in various pathological conditions in vivo where local Ang II production is enhanced (38, 43) . Recently, a novel mechanism of ligand-independent induction of apoptosis by AT2 receptor expression per se has been reported in R3T3 fibroblasts and vascular smooth muscle cells (44) . Whether such a mechanism is operative in postconfluent WKY-MC to induce growth inhibition and/or apoptosis remains to be clarified.
What leads to the lower expression of the AT2 receptor in the SHRSP kidney is another issue to be addressed. We have already shown that the AT2 receptor is upregulated in vitro upon contact inhibition in mouse R3T3 fibroblasts (14) and WKY-MC (13), but not in SHRSP-MC (13) . Such differential inducibility of the AT2 receptor with impaired induction in SHR has also been reported in vascular smooth muscle cells under serum depletion (45) . In an attempt to explore the underlying mechanism, we have already revealed that transcriptional factors IRF-1 and -2 upon binding to the IRFbinding element of the promoter play a critical role in growth-dependent regulation of AT2 receptor expression in R3T3 fibroblasts (14) . The present study has shown that there is no sequence difference around the IRF-binding motif of the AT2 receptor gene between SHRSP and WKY. We then examined the expression of IRF-1 in MC. We found that the AT2 receptor expression paralleled the IRF-1 expression, and that the AT2 receptor expression was significantly (by 20 -25%) inhibited by IRF-1 antisense ODN treatment (Fig. 3) . Considering the low ( 30%) transfection efficiency, these findings suggest that the mesangial AT2 receptor expression is largely dependent on IRF-1 expression. We also found that the AT2 receptor could be induced in SHRSP-MC by stimulation with IFNs, as in R3T3 cells (26) . This induction was rather rapid (Fig. 3C) , and therefore might involve the modulation by IFNs of IRF-1 at the protein level, such as through phosphorylation, in addition to its transcriptional activation (46) . Whether IRF-1 also regulates the AT2 receptor expression in the fetal and neonatal kidney in vivo remains to be clarified. Although our preliminary data did not show any apparent difference of IRF-1 or -2 mRNA levels in the kidney between SHRSP and WKY (not shown), this finding is still inconclusive because the precise distribution and correlation within the tissues and cells have not been clarified.
In summary, we have revealed that the AT2 receptor expression in the SHRSP kidney is significantly lower than that in the WKY kidney during the perinatal period. Impairment of AT2 receptor expression in SHRSP-MC is at least partly due to inefficient IRF-1 induction. The question of whether this difference of AT2 receptor expression is involved in the pathogenesis of hypertension and renal injury awaits further investigation. Nevertheless, the present study suggests the possibility that the unbalanced AT1/AT2 receptor expression in SHRSP, with exaggerated renal AT1 signaling during the 
